ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for neffy® (epinephrine nasal spray)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/6/2026

1. ZS
2. LULU
3. IOT
4. SPY
5. PATH
6. DOCU
7. ASAN
8. NVDA
9. CIEN
10. GWRE

Go back to ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for neffy® (epinephrine nasal spray)

William Blair Reiterates Outperform Rating on ARS Pharmaceuticals Inc (SPRY)

November 10, 2025 7:29 AM EST

William Blair analyst Tim Lugo reiterated an Outperform rating on ARS Pharmaceuticals Inc (NASDAQ: SPRY).

The analyst comments "We attended the American College of Allergy, Asthma, and Immunology (ACAAI) 2025 annual meeting where ARS presented the initial results from the neffyExperience program alongside a number of posters on neffy. Based on a... More